We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+23.92%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$610M
AUM Growth
+$210M
Cap. Flow
+$121M
Cap. Flow %
19.85%
Top 10 Hldgs %
60.54%
Holding
32
New
6
Increased
15
Reduced
6
Closed
5

Top Buys

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$41.1M
2
OPCH icon
Option Care Health
OPCH
+$27.7M
3
CADX
CADENCE PHARMACEUTICALS, INC COM STK
CADX
+$18.8M
4
ENDP
Endo International plc
ENDP
+$16.6M
5
OSIR
Osiris Therapeutics, Inc. Common Stock
OSIR
+$15.6M

Top Sells

Rank Stock Value
1
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$43.1M
2
AFFX
Affymetrix Inc
AFFX
+$21.3M
3
BIIB icon
Biogen
BIIB
+$14.4M
4
FURX
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
+$4.64M
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$4.05M

Sector Composition

Rank Sector Weight
1 Healthcare 62.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$26.2B
$65.4M 10.73%
578,690
+110,500
+24% +$9.96M
WX
2
DELISTED
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
$48.1M 7.88%
1,252,314
+250,800
+25% +$7.92M
ENDP
3
DELISTED
Endo International plc
ENDP
$45.3M 7.42%
670,900
+290,600
+76% +$16.6M
AEGR
4
DELISTED
Aegerion Pharmaceuticals
AEGR
$38.1M 6.25%
+537,034
New +$41.1M
CSII
5
DELISTED
Cardiovascular Systems, Inc.
CSII
$37.5M 6.15%
1,093,234
+214,980
+24% +$6.25M
OPCH icon
6
Option Care Health
OPCH
$3.36B
$29M 4.76%
+980,333
New +$27.7M
FURX
7
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
$27.3M 4.47%
648,829
-112,935
-15% -$4.64M
INSY
8
DELISTED
Insys Therapeutics, Inc.
INSY
$27M 4.43%
2,093,289
+869,694
+71% +$12.1M
TARO
9
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$26.1M 4.28%
263,732
+3,649
+1% +$316K
MDCO
10
DELISTED
Medicines Co
MDCO
$25.5M 4.19%
661,355
-80,000
-11% -$2.86M
EBS icon
11
Emergent Biosolutions
EBS
$375M
$25.1M 4.12%
1,093,828
+59,959
+6% +$1.25M
AMAG
12
DELISTED
AMAG Pharmaceuticals
AMAG
$25.1M 4.12%
1,034,537
+91,500
+10% +$2.15M
CADX
13
DELISTED
CADENCE PHARMACEUTICALS, INC COM STK
CADX
$23.6M 3.87%
+2,608,180
New +$18.8M
ENTA icon
14
Enanta Pharmaceuticals
ENTA
$378M
$23.2M 3.81%
851,294
+281,801
+49% +$6.83M
SLXP
15
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$23.2M 3.8%
257,779
-30,000
-10% -$2.39M
ANAC
16
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$23M 3.77%
1,369,880
+632,195
+86% +$8.75M
OFIX icon
17
Orthofix Medical
OFIX
$477M
$21.2M 3.48%
931,052
+288,326
+45% +$6.03M
OSIR
18
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$15.7M 2.57%
+976,016
New +$15.6M
HPTX
19
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$14.8M 2.43%
734,296
+651,154
+783% +$15.3M
RXII
20
DELISTED
GALENA BIOPHARMA INC COM
RXII
$14.8M 2.43%
+2,986,946
New +$14.8M
SCMP
21
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$8.7M 1.43%
925,214
+70,000
+8% +$499K
CLVS
22
DELISTED
Clovis Oncology, Inc.
CLVS
$8.58M 1.41%
142,300
+800
+0.6% +$43.5K
CHDX
23
DELISTED
CHINDEX INTL INC
CHDX
$6.33M 1.04%
363,429
+10,000
+3% +$165K
MASI
24
DELISTED
Masimo
MASI
$4M 0.66%
+136,875
New +$3.83M
LPDX
25
DELISTED
LIPOSCIENCE INC COM
LPDX
$1.88M 0.31%
443,052
-2,000
-0.4% -$8.79K
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q4 2013 Portfolio in Review

As of Q4 2013, Consonance Capital Management held 32 positions worth $610M, up 53% from $400M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Consonance Capital Management deployed $121M of net new capital in Q4 2013, opening 6 new positions and adding to 15 existing holdings. Its largest new stake was Aegerion Pharmaceuticals: 537,034 shares worth $38.1M.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, up from 49% a quarter earlier.

On the sell side, the largest reduction was FURIEX PHARMACEUTICALS INC COM STK (DE), an estimated $4.64M trimmed.

  • Consonance Capital Management's largest Q4 2013 buy was Aegerion Pharmaceuticals: 537,034 shares worth $38.1M.
  • Consonance Capital Management added most to Endo International plc in Q4 2013, an estimated $16.6M increase.
  • Consonance Capital Management's biggest Q4 2013 reduction was FURIEX PHARMACEUTICALS INC COM STK (DE), cutting an estimated $4.64M.
  • Consonance Capital Management fully exited NPS PHARMACEUTICALS INC in Q4 2013, selling an estimated $43.1M.
  • Consonance Capital Management's ten largest holdings make up 61% of its $610M portfolio in Q4 2013.
  • Consonance Capital Management opened 6 new positions and closed 5 in Q4 2013.
  • Consonance Capital Management's portfolio value rose 53% quarter-over-quarter to $610M.

Based on Consonance Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.